Title | Multiple Organ Failure [electronic resource] : Pathophysiology, Prevention, and Therapy / edited by Arthur E. Baue, Eugen Faist, Donald E. Fry |
---|---|
Imprint | New York, NY : Springer New York : Imprint: Springer, 2000 |
Connect to | http://dx.doi.org/10.1007/978-1-4612-1222-5 |
Descript | XXII, 712 p. online resource |
I Development of SIRS, MODS, and MOF -- 1. History of MOF and Definitions of Organ Failure -- 2. SIRS, MODS, and the Brave New World of ICU Acronyms Have They Helped Us? -- 3. Systemic Inflammatory Response and Multiple Organ Dysfunction Syndrome: Biologic Domino Effect -- 4. Risk Factors for MOF and Pattern of Organ Failure Following Severe Trauma -- 5. Risk and Setting for Multiple Organ Failure in Medical Patients -- 6. Epidemiology, Risk Factors, and Outcome of Multiple Organ Dysfunction Syndrome in Surgical Patients -- II Mechanisms of SIRS and Organ Failure -- 7. Systemic Inflammation After Trauma, Infection, and Cardiopulmonary Bypass; Is Autodestruction a Necessary Evil? -- 8. Cardiopulmonary Bypass for Cardiac Surgery;An Inflammatory Event: Can It Be Modulated? -- 9. Gut: Clinical Importance of Bacterial Translocation, Permeability, and Other Factors -- 10. Mcrocirculatory Arrest Theory of SIRS and MODS -- 11. Infection, Bacteremia, Sepsis, and the Sepsis Syndrome: Metabolic Alterations, Hypermetabolism, and Cellular Alterations -- 12. Ischemia and Reperfusion as a Cause of Multiple Organ Failure -- 13. Endotoxin in Human Disease and Its Endogenous Control -- 14. Untimely Apoptosis in Human SIRS, Sepsis, and MODS -- 15. Immunosuppression with Injury and Operation and Increased Susceptibility to Infection -- III Mediators and Effectors -- 16. Emerging Evidence of a More Complex Role for Proinflammatory and Antรผnflammatory Cytokines in the Sepsis Response -- 17. Counterregulation of Severe Inflammation: When More Is Too Much and Less Is Inadequate -- 18. Reactive Oxygen Species in Clinical Practice -- 19. Nitric Oxide as a Modulator of Sepsis: Therapeutic Possibilities -- 20. Mast Cells -- 21. Eicosanoids -- 22. Platelet-Activating Factor -- 23. Therapeutic Complement Inhibition -- 24. LeukocyteโEndothelial Cell Interactions: Review of Adhesion Molecules and Their Role in Organ Injury -- IV Prevention and General Therapy -- 25. Care of Injured Patients in the Field, During Transport, and in the Emergency Department -- 26. Intensive Care Monitoring -- 27. Peritonitis: Management of The Patient with SIRS and MODS -- 28. HypothermiaโCoagulopathyโAcidosis Syndrome: When to Operate/When to Stop Operating -- 29. Early Definitive Fracture Fixation with Polytrauma: Advantages Versus Systemic/Pulmonary Consequences -- 30. Abdominal Compartment Syndrome -- 31. SIRS and MODS: Indications for Surgical Intervention? -- 32. Nosocomial Infections in the ICU -- 33. Modulation of the Hypermetabolic Response After Trauma and Burns -- V Specific Remote Organ Failures -- 34. Circulation -- 35. Effect of Inflammatory Conditions on the Heart -- 36. Lung -- 37. Renal Function and Dysfunction in Multiple Organ Failure -- 38. Metabolic Depletion and Failure: Muscle Cachexia During Injury and Sepsis -- 39. Immunomodulation of Cell-Mediated Responses: Is It Feasible? -- 40. Central Nervous System Failure: Neurotrauma Trials -- 41. Stress Gastritis: Is It a Disappearing Disease? -- 42. Gut and the Immune System: Enteral Nutrition and Immunonutrients -- 43. Disseminated Intravascular Coagulation -- 44. Refunctionalization of the Gut -- 45. Liver: Multiple Organ Dysfunction and Failure -- 46. Liver: Hepatic Support and the Bioartificial Liver -- VI Therapeutic Horizons -- 47. Laboratory Markers to Support Early Diagnosis of Infection and Inflammation -- 48. Endotoxin Antagonists -- 49. Blood Purification Therapy to Prevent or Treat MOF -- 50. Antithrombin III and Tissue Factor Pathway Inhibitor: Two Physiologic Protease Inhibitors of the Coagulation System -- 51. Rationale for Glucocorticoid Treatment in Septic Shock and Unresolving ARDS -- 52. Pathophysiologic and Clinical Importance of Stress-Induced Th1/Th2 T Cell Shifts -- 53. Pathophysiologic and Clinical Role of Interferon-? and Its Release Triggering Cytokines IL-12 and IL-18 -- 54. Interleukin-11: Potential Therapeutic Activity in Systemic Inflammatory States -- 55. Minimal Surgical Procedures to Decrease the Stress Response and New Potential Therapeutic Agents -- 56. Wound Healing: Physiology, Clinical Progress, Growth Factors, and the Secret of the Fetus -- 57. Problems with Magic Bullets: Future Trials and Multiagent Therapy -- 58. Maximizing Oxygen Delivery and Consumption: In Whom and for Whom? -- 59. Gut Decontamination: Prevention of Infection and Translocation -- 60. Myocardial Depression: Is It Clinically Relevant? -- 61. Infection: Cause or Result of Organ Failure? -- 62. Hypertonic Solutions -- 63. Blood Substitutes -- 64. Growth Factors G-CSF and GM-CSF: Clinical Options -- 65. Anabolic Effects of Growth Hormone in Critically Ill Patients -- 66. Immunoglobulin Therapy: Where Does It Stand Clinically? -- 67. Horizons in the Anesthetic Care of Injured, Operated, and Stressed Patients -- 68. Integrative Biology and Genetic Variability: MODSโ Next Frontiers -- 69. Are We Making Progress in Preventing and Treating MOF? -- 70. Ethical Considerations of MODS, SIRS, and MOF -- 71. Socioeconomic Impact of Multiple Organ Failure -- 72. Future Directions in the Treatment of SIRS and MODS -- 73. Summary and Overview: What Does the Future Hold?